BRGX · XBRL financial data
Bioregenx financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (BRGX's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|
| Revenue | 42 | 22 | 2,340 | 1,855 |
| Cost of revenue | 0 | 1,100 | 682 | 351 |
| Gross profit | 42 | 2,311 | 1,658 | 1,504 |
| Research and development | — | 258 | 0 | 32 |
| Selling, general and administrative | — | 5,229 | 5,851 | 2,007 |
| Total operating expenses | 120 | 132 | 24,422 | 2,748 |
| Operating income (loss) | (78) | (110) | (22,763) | (1,244) |
| Interest expense | 0 | 8 | 291 | 300 |
| Income tax expense (benefit) | 0 | 0 | — | — |
| Net income (loss) | (78) | (571) | (23,054) | (1,544) |
| Earnings per share, basic USD per share | 0.00 | 0.00 | (0.02) | 0.00 |
| Earnings per share, diluted USD per share | 0.00 | 0.00 | (0.02) | 0.00 |
| Weighted average shares, basic thousands of shares | 269,745 | 276,367 | 939,510 | 959,710 |
| Weighted average shares, diluted thousands of shares | 269,745 | 276,367 | 939,510 | 959,710 |
Balance sheet
CSVFiscal years (BRGX's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|
| Cash and cash equivalents | 1 | 125 | 58 | 69 |
| Accounts receivable | — | 105 | 15 | 40 |
| Inventory | — | 218 | 111 | 107 |
| Prepaid and other current assets | — | 205 | 123 | 35 |
| Total current assets | 1 | 0 | 308 | 251 |
| Property and equipment, net | — | 14 | 201 | 160 |
| Goodwill | — | 0 | — | — |
| Total assets | 59 | 32 | 509 | 411 |
| Accounts payable | — | 242 | 427 | 616 |
| Accrued liabilities | — | 347 | 453 | 434 |
| Current portion of long-term debt | 4 | 200 | 883 | 1,003 |
| Total current liabilities | 65 | 254 | 3,633 | 4,066 |
| Long-term debt | 196 | 0 | 255 | 182 |
| Total liabilities | 261 | 254 | 3,888 | 4,948 |
| Accumulated deficit | (2,918) | (3,510) | (35,572) | (37,116) |
| Total stockholders' equity | (202) | (222) | (3,379) | (4,537) |
| Total liabilities and equity | 59 | 32 | 509 | 411 |
| Common shares outstanding (cover page) thousands of shares | 273,750 | 956,630 | 956,994 | 969,017 |
Cash flows
CSVFiscal years (BRGX's year ends in late December)
| In thousands of dollars | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|
| Net income (loss) | (78) | (571) | (23,054) | (1,544) |
| Stock-based compensation | — | 2,238 | 2,851 | 0 |
| Depreciation and amortization | — | 4 | 2,219 | 75 |
| Net cash from operating activities | (65) | (13) | (324) | 39 |
| Purchases of property and equipment | — | 0 | 189 | 9 |
| Net cash from investing activities | 0 | 0 | (188) | (59) |
| Proceeds from issuing common stock | — | 1,342 | 0 | — |
| Net cash from financing activities | 41 | 13 | 442 | 33 |
| Net change in cash | — | (491) | (67) | 11 |
Compare with peers
SIC 7370 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 7370 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Bioregenx | 46 | 426 | 27 | 971.6M | — | 10-QMar 31, 2026 |
| Auddia | 9,558 | 7.6 | (2,508)* | 5.8M | 3.8 quarters | 10-QJun 30, 2026 |
| Powerdyne International | 73 | 256 | (77)* | 2.0B | 0.9 quarters | 10-QJun 30, 2026 |
| My Size | 453 | 3,070 | 25* | 728,482 | — | 10-QJun 30, 2026 |
| ZW Data Action Technologies | 611 | 652 | (108)* | 3.7M | 5.7 quarters | 10-QJun 30, 2026 |
| Super League Enterprise | 1,127 | not reported | (2,201)* | 1.7M | 3.0 quarters | 10-QJun 30, 2026 |
| Versus Systems | 1,362 | 6.8 | (475)* | 6.2M | 2.9 quarters | 10-QJun 30, 2026 |
| Onfolio Holdings | 251 | 1,498 | (611)* | 2.5M | 0.4 quarters | 10-QJun 30, 2026 |
| Techlott | 495 | not reported | (316)* | 890.7M | 1.6 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.